



Gilead UK and Ireland Fellowship Programme 2014 HIV, viral hepatitis, invasive fungal disease, cystic fibrosis

Following the success of the Gilead UK and Ireland Fellowship Programme (GUKIFP) from 2009 to 2013, we are pleased to provide details for an expanded Fellowship Programme for 2014, which aims to provide funding amounting to £675,000.

The aim of the Gilead UK and Ireland Fellowship Programme is to award financial grants (or support and contribution to joint working initiatives between the NHS and Gilead or the NHS, Gilead and the third sector) to generate and promote best practice in the delivery of patient-centred care through innovative and reproducible models in HIV, viral hepatitis (hepatitis C virus (HCV)), invasive fungal disease (IFD) and cystic fibrosis (CF).

In the Fellowship Programme, financial grants or support will be awarded on a competitive basis to individual organisations or groups of local healthcare providers such as, but not limited to, hospital clinics and patient organisations. In 2014 funding will be awarded to applicants whose proposals best demonstrate:

HIV

Up to £200,000 will be available for projects in any of the following areas:

- Retention in HIV treatment and care, including transfers
- Provision of outpatient care with consideration for co-morbidity/ies
- Access to multidisciplinary team ARV advice, supporting equity of prescribing (eg for smaller centres)

The projects can be local, regional, network-affiliated or national.

Viral hepatitis

Up to £300,000 will be available for projects in any of the following areas:

- Targeted, locally based initiatives to increase diagnosis of HCV in high risk populations which demonstrate successful onward referral to specialist care
- Targeted locally based initiatives to re-engage individuals who had been diagnosed with HCV but lost to follow up individuals with the hepatitis care pathway

IFD

Up to £100,000 will be available for projects in any of the following areas:

- Reasons for early initiation of systemic antifungal treatment
- Understanding how response to treatment and/or risk stratification are drivers for prolonged systemic antifungal therapy
- Characterisation of systemic antifungal treatment failure due to breakthrough infections or resistance
- Changes to care pathways that may include integration of diagnostics and CT and consequent step-down therapy

The main focus of the projects should be on any one or more of the following:

- impact on clinical outcomes
- patient satisfaction
- cost of disease management

The projects can be local, regional, network-affiliated or national.

CF

The 2014 CF programme is to be run in partnership with the CF Trust – details to be announced soon.

Applications can be made through the Gilead Fellowship website www.ukifellowshipprogramme.com, please visit for application closing dates and further information.